Thursday, 15 October 2026European Markets

HIGH CO And DEKUPLE Have A High Dividend Yield And Return On Equity In The Advertising Agencies Industry.

Loading stream...

(vianews) - high co (hco.pa) is among this list of stock assets with the highest dividend rate and return on equity on the advertising agencies industry.

financial asset price forward dividend yield return on equity
high co (hco.pa) €2.79 9.3% 3.99%
dekuple (dkupl.pa) €28.40 3.13% 26.04%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. high co (hco.pa)

9.3% forward dividend yield and 3.99% return on equity

high co. sa provides marketing solutions to various retailers and brands worldwide. the company offers brand platform, communication strategy, social media engagement, and media strategy services; and service design services, sms and push notifications, mobile applications and websites, and loyalty programs. it also provides data collection and analysis, targeting and personalization drivers, predictive algorithms, and gdpr compliant technologies; and promotion mechanics, multi-channel distribution, logistics and merchandising, and operational management and coupon processing services. the company was founded in 1990 and is headquartered in aix-en-provence, france.

earnings per share

as for profitability, high co has a trailing twelve months eps of €0.19.

pe ratio

high co has a trailing twelve months price to earnings ratio of 14.68. meaning, the purchaser of the share is investing €14.68 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.99%.

more news about high co.

2. dekuple (dkupl.pa)

3.13% forward dividend yield and 26.04% return on equity

adlpartner sa provides marketing solutions in france and internationally. the company designs, markets, and implements customer loyalty and relationship management services; markets and sells magazine press subscriptions; and offers marketing solutions and insurance brokerage services. it also provides consulting and technology, marketing engineering agency, and creator of customer relation services. the company was founded in 1972 and is based in montreuil, france. adlpartner sa is a subsidiary of sogespa sas.

earnings per share

as for profitability, dekuple has a trailing twelve months eps of €2.25.

pe ratio

dekuple has a trailing twelve months price to earnings ratio of 12.62. meaning, the purchaser of the share is investing €12.62 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 26.04%.

dividend yield

as stated by morningstar, inc., the next dividend payment is on jun 21, 2023, the estimated forward annual dividend rate is 0.88 and the estimated forward annual dividend yield is 3.13%.

more news about dekuple.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com